Photodynamic Therapy for Basal Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa by Lee, Myn Wee et al.
International Scholarly Research Network
ISRN Dermatology
Volume 2011, Article ID 346754, 4 pages
doi:10.5402/2011/346754
Case Report
Photodynamic Therapy forBasalCell Carcinomain Recessive
DystrophicEpidermolysis Bullosa
Myn Wee Lee,1 GeorgeVarigos,1 Peter Foley,2,3,4 and GayleRoss1
1Department of Dermatology, The Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia
2Department of Medicine, The University of Melbourne, Parkville, VIC 3050, Australia
3Department of Dermatology, St. Vincent’s Hospital, Fitzroy, VIC 3065, Australia
4Skin and Cancer Foundation, 80 Drummond Street, Carlton, VIC 3053, Australia
Correspondence should be addressed to Myn Wee Lee, mynwee@ymail.com
Received 19 February 2011; Accepted 24 March 2011
Academic Editor: C. Ferr´ andiz
Copyright © 2011 Myn Wee Lee et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A 22-year-old male with recessive dystrophic epidermolysis bullosa with a large superﬁcial and nodular basal cell carcinoma on
his right forehead was treated with photodynamic therapy. The treatment was well tolerated, and the site healed well. Patients
with epidermolysis bullosa are at increased risk of developing skin cancers, particularly squamous cell carcinomas. However,
basal cell carcinomas are rare in recessive dystrophic epidermolysis bullosa. As patients with epidermolysis bullosa have recurrent
blisteringandpoorwoundhealing,surgerymaynotbe the optimalchoice intreating skincancers.Wepresent thiscasetohighlight
that photodynamic therapy may be a helpful and safe technique in the treatment of superﬁcial skin cancers in patients with
epidermolysis bullosa, as an alternative to more radical methods.
1.Introduction
Epidermolysisbullosa(EB)encompassesagroupofinherited
skin fragility disorders, characterised by blistering of the skin
and mucous membranes following minimal trauma [1]. EB
is divided into distinct subtypes based on the level of blister
formation within the skin, each subtype having diﬀerent
genetic mutations. Dystrophic epidermolysis bullosa (DEB)
is caused by mutations in the gene COL7A1, which encodes
type VII collagen, the predominant anchoring ﬁbril protein
at the dermal-epidermal junction [2]. Therefore, cleavage
occurs beneath the lamina densa of the cutaneous basement
membrane. Abnormality in the number and appearance of
anchoring ﬁbrils which serve as adhesion structures leads to
extreme mucocutaneous fragility and formation of chronic
wounds, which have an impaired ability to heal [3]. Blisters
within the sublamina densa region of the skin elicit a
ﬁbrosingresponseinthedermis,whichexplainsthetendency
of healing with extensive scarring [2]. DEB is inherited in
autosomal dominant or recessive pattern, which contributes
to the variable clinical spectrum of the disease.
2.Case Report
Our patient was diagnosed with Hallopeau-Siemens dys-
trophic recessive epidermolysis bullosa (DREB) in infancy,
characterized by severe fragility and blistering of his skin.
Complicationshaveincludedmittendeformitiesofthehands
and contractures in his hips, knees, and ankles, resulting in
him being wheelchair bound for more than 10 years. He has
recurrent oesophageal strictures, anaemia (chronic disease
and iron deﬁciency), and secondary hypogonadism. Given
his medical condition,the patient’s lifestyle is predominantly
indoors, with minimal sun exposure. He has no known
family history of skin cancers and has never been exposed
to gamma radiation in the past.
A chronic lesion was noted on routine skin check on
the patient’s right forehead (Figure 1). The patient had been
applying a potent topical steroid to the area. Biopsies taken
from the centre of the lesion conﬁrmed a superﬁcial basal
cell carcinoma (BCC), whilst the edge had a nodular growth
pattern.
Given the size of the tumour, which would have required
excisionandgrafting,itwashypothesizedthatphotodynamic2 ISRN Dermatology
Figure 1: Superﬁcial basal cell carcinoma on patient’s right
forehead, with nodular growth pattern at the periphery.
Figure 2: The same lesion 4 months after PDT.
therapy(PDT)may potentiallybeaneﬀectivetreatment with
improved healing and better cosmesis than excision.
Photodynamic therapy was performed. The area was
marked with a 5mm margin. No curettage was performed.
Methyl-ALA (Metvix) cream was applied to the area and
allowed to penetrate for 3 hours under an occlusive dressing.
The area was then irradiated using an Aktilite lamp for 8
minutes 45 seconds at 37J/cm2 and the whole procedure
was repeated two weeks later. The patient experienced an
inﬂammatory reaction expected with PDT. Following the
treatment, the site healed steadily over the following 3-4
weeks, with minimal scarring. The entire procedure was well
tolerated by the patient and he did not report any signiﬁcant
side eﬀects.
On a subsequent follow-up visit 4 months later, it
was noted that there was some residual nodular BCC at
the edge of the lesion, which had not responded to the
PDT (Figure 2). This was conﬁrmed on biopsy, which
revealed granulation tissue in the centre of the lesion, with
nodular BCC at the edges. A trial of Imiquimod cream was
commenced for a duration of six weeks. The cream was
applied ﬁve days a week (Monday to Friday), once daily.
Figure3:Postexcisionandsplitskingraftingoftheresidualnodular
basal cell carcinoma.
The patient reported an inﬂammatory reaction and slight
improvement in the appearance ofthe lesion. Twelve months
after the PDT, the patient underwent excision and split skin
grafting of the entire area due to continued presence of BCC.
Histology conﬁrmed BCC, and the lesion was completely
excised. The recipient site healed uneventfully, although the
cosmesis was poor (Figure 3). The graft donor site remained
an area of poor healing 1 year postoperatively.
3.Discussion
In severe generalised recessive DEB (Hallopeau-Siemens),
as in our patient, extensive bullae develop from infancy.
Clinical presentations include blisters, scarring associated
with milia formation, chronic erosions, and ulcers. Repeated
blistering and progressive scarring can result in fusion of
digits, which may progress to contractures and deformities.
Other features include alopecia associated with scarring of
the scalp and blistering and stricture of the oesophagus
resulting in dysphagia and obstruction.
The most serious complication of DEB is the develop-
ment of multiplesquamous cell carcinomas (SCCs),which is
t h em a j o rc a u s eo fm o r b i d i t ya n d mortality in these patients
[4]. The formation of SCCs is associated with chronic,
nonhealingwounds,aspresentinpatientswithEB.Therefore
it is crucial that malignant lesions are identiﬁed early and
treated aggressively in patientswith EB. However,assessment
o fs k i nc a n c e r si nE Bp a t i e n t si so f t e nd i ﬃcult, due to
widespreadulceration,scarring,andcrustingpresentinthese
patients [4].
Interestingly, BCCs are uncommon. The National EB
Registry in the United States, which has 3280 patients listed,
failed to identify any RDEB patients with BCC. Cases of
BCC are seen in patients with severe EB simplex [5]. This
is possibly explained by the fact that blistering in EB simplex
occurs within the basal keratinocytes, from which BCCs are
known to arise [5].
Given our patient’s young age and absence of signiﬁcant
risk factors, it is unusual that he developed a BCC on his
forehead. There are several theories as to why this may haveISRN Dermatology 3
occurred. It is widely accepted that BCCs are ultraviolet
(UV)induced;however,therearevariousgenesimplicatedin
the carcinogenesis of BCCs. Mutations of the TP53 tumour
suppressor gene and the sonic hedgehog pathway (SHH)
genes PTCH and SMOH are found in both sporadic and
hereditary forms of BCCs [6]. A study done by Reifenberger
et al. found that while 72% of TP53 mutations were
presumably UV induced, the “UVsignature” was present in
only 40% of PTCH and SMOH mutations [6]. This suggests
that there may be other mechanisms, other than UVR that
trigger tumourigenesis in BCCs. Genetic analysis was not
performed in this case, if carried out could possibly shed
some light on this issue.
There have been rare reports of BCCs developing within
chronic wounds; however, this is most commonly associated
with chronic venous ulcers on the legs [7] .W h e t h e ro rn o t
this is as in our patient’s case is unclear. It seems more likely
thattheBCChadbeenpresentforasigniﬁcantperiodoftime
but had been mistaken for a chronic wound and therefore
allowed to proliferate. The potent topical steroid use may
also have resulted in the lesion becoming larger and more
atrophic than usual.
Topical photodynamic therapy has been approved in 18
countries worldwide for treatment of various skin cancers,
including BCC [8] .P D Tw h e ne m p l o y e di nt r e a t m e n to f
BCCsdeliverssuperiorcosmesisthanothermodesoftherapy
including surgery and cryotherapy. 87–98% of nBCC had
good/excellent cosmesis at 5 years compared with 54% of
patients who underwent surgery [8]. However, eﬃcacy of
PDT is higher in treating superﬁcial BCCs compared to
nodular BCCs, with surgery remaining the gold standard for
treatment ofnBCC[8].Itisfeltthatthe roleofPDTinnBCC
is where surgery is suboptimal and cosmesis is important,
suchasinourpatient.Givenhis medicalcondition,therewas
a high likelihood that surgery would result in a wound that
was slow to heal.
There has been a lack of the literature addressing the
employment of PDT in treatment of skin cancers in patients
with EB. Souza and colleagues reported a case of Bowen’s
disease on the ring ﬁnger of a female patient with non-
Hallopeau-Siemensrecessive DEB,which was treated with 5-
aminolaevulinic acid PDT with good clinical outcome. The
treated area healed within 4 weeks, with no recurrence of BD
at 2-year followup [9]. There are no cases of PDT use in HS-
RDEB or for BCCs in patients with EB.
4.Conclusion
We believe that this case demonstrates the potential eﬃcacy
and healing of a large superﬁcial and nodular BCC in
a patient with HS-RDEB. Although surgery unfortunately
could not be avoided, we would like to highlight that
the reaction generated by PDT was very well tolerated
by the patient, and the lesion healed completely. There
are several reasons why he ultimately failed to clear the
nBCC component. Firstly, the lesion was not curetted due
to concerns about skin fragility. This may have hampered
control of the nodular component. Secondly, the margin
and amount of Metvix may have been insuﬃcient. Perhaps
a further PDT treatment may have been successful when
combined with curettage. However, as this was a large BCC
in a relatively high risk site, it was not felt that further
risks could be taken, and excision and grafting was deemed
necessary. As such, surgery remains the ﬁrst-line treatment
for nBCC; however, we feel that PDT warrants consideration
when there is a role for other methods.
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